SEP 8, 2026 · JOURNAL ARTICLE
Prognostic Value of the Lung Immune Prognostic Index in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab: A Real-World Analysis Beyond PD-L1 Expression
Diagnostics
Real-world retrospective single-center analysis showing LIPI independently predicts survival in nivolumab-treated advanced NSCLC with statistically significant stratification and improved model discrimination, but limited by retrospective design, single center, and lack of external validation.
Reported
Median PFS (LIPI 0)566 days
Median PFS (LIPI 1)340 days
Median PFS (LIPI 2)109 days